Ex-vivo expansion of CFU-GM and BFU-E in unselected PBMC cultures with Flt3L is enhanced by autologous plasma

Cytotherapy

Volumn 1, Issue 3, 1999, Pages 183-194

  Guo, M ^a,b   Miller, W M ^a,b,c   Papoutsakis, E T ^a,b,c   Patel, S ^b,c   James, C ^a   Goolsby, C ^a   Winter, J N ^a,b,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University   (United States)

^d NW Univ Feinberg School of Medicine   (United States)

Author keywords

Ex vivo expansion; Stem cell transplantation

Indexed keywords

EID: 0007095770     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653249910001591266     Document Type: Article

References (43)

1. Emerson SG. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood 1996;87:3082-8.
2. Brugger W, Heimfeld S, Berenson RJ et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283-7.
3. + cells in autologous stem cell transplantation for breast cancer. Blood 1996;87:1687-91.
4. Bertolini F, Battaglia M, Pedrazzoli P et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997;89:2679-88.
5. Stiff P, Oldenberg E, His B et al. Transplantation of ex vivo expanded cells grown in Aastrom stromal-based perfusion bioreactors from small marrow aliquots (40 mL) produces durable hematopoietic reconstitution after ablative chemotherapy. Blood 1997;90 (Suppl 1):395a.
6. +-selected cells can abrogate post-myeloablative chemotherapy neutropenia in patients with hematologic malignancies. Blood 1998;92 (Suppl 1):126a.
7. - cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colonystimulating factor. Blood 1991;77:2316-21.
8. McNiece I, Langley KE, Zsebo K. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myleoid and erythroid lineages. Exp Hematol 1991;19:226-31.
9. Purdy MH, Hogan CJ, Hami E et al. Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation. J Hematother 1995;4:515-25.
10. + cells: Effects of hematopoietic growth factors on production of neutrophilic precursors. J Hematother 1997;6:475-89.
11. Lyman SD, James L, Johnson L et al. Cloning of the human homologue of the murine Flt-3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 1994;83:2795-801.
12. Lyman SD, Jacobsen SEW. c-kit ligand and Flt3 ligand: Stem/ progenitor cell factors with overlapping yet distinct activities. Blood 1998;91:1101-34.
13. + bone marrow progenitor cells in vitro. Blood 1996;87:1317-25.
14. Gabbianelli M, Pelosi E, Montesoro E et al. Multi-level effects of Flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/ monocytic precursors. Blood 1995;86:1661-70.
15. Koller MR, Oxender M, Brott DA, Palsson B. Flt3 ligand is more potent than c-kit ligand for the synergistic stimulation of ex vivo hematopoietic cell expansion. J Hematother 1996; 5:449-59.
16. + hematopoietic progenitor cells. Blood 1995;86:3413-20.
17. + cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells. Blood 1995;86:958-70.
18. Koller MR, Manchel I, Newsom B et al. Bioreactor expansion of human bone marrow: comparison of unprocessed, density-separated, and CD34-enriched cells. J Hematother 1995; 4:159-69.
19. Collins PC, Nielsen LK, Wong C-K et al. Real-time method for determining the colony-forming cell content of human hematopoietic cell cultures. Biotech Bioeng 1997;55:693-700.
20. Lill MC, Lynch M, Fraser JK, Chung GY et al. Production of functional myeloid cells from CD34-selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system. Stem Cells 1994;12:626-37.
21. Thomas JW, Baum CM, Hood WF et al. Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. Proc Natl Acad Sci USA 1995;92:3779-83.
22. Stelzer GT, Marti G, Huley A et al. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 1997;30:214-30.
23. Sandstrom CE, Miller WM, Papoutsakis ET. Serum-free media for cultures of primitive and mature hematopoietic cells [Review]. Biotech Bioeng 1994;43:706-33.
24. Terstappen LWMM, Buescher S, Nguyen M, Reading C. Differentiation and maturation of growth factor expanded human hematopoietic progenitors assessed by multidimensional flow cytometry. Leukemia 1992;6:1001-10.
25. McAlister IB, Teepe M, Gillis S, Williams DE. Ex vivo expansion of peripheral blood progenitor cells with recombinant cytokines. Exp Hematol 1992;20:626-8.
26. Takaue Y, Abe T, Kawano Y et al. Combination of recombinant cytokines fails to produce ex vivo expansion of human blood hematopoietic progenitor cells. Ann Hematol 1992;64:217-20.
27. + cells. Blood 1993;82:3600-9.
28. + hematopoietic progenitors elicited from human fetal liver, umbilical cord blood, bone marrow and mobilized peripheral blood. J Hematother 1996;5:655-62.
29. + progenitor cells by stem cell factor, interleukin-1β (IL-1β), IL-6, IL-3, interferon-γ, and erythropoietin. Blood 1993;81:2579-84.
30. Haylock DN, Horsfall MJ, Dowse TL et al. Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of Flt3 ligand. Blood 1997;90:2260-72.
31. Sandstrom CE, Collins PC, McAdams TA et al. Comparison of whole serum-deprived media for ex vivo expansion of hematopoietic progenitor cells from cord blood and mobilized peripheral blood mononuclear cells. J Hematother 1996;5:461-73.
32. + cells from patients with Stage IV breast cancer. Blood 1994;84:3567-74.
33. + cells. J Exp Med 1996;183:837-45.
34. Wu H, Klingmuller U, Besmer P, Lodish HF. Interaction of the erythropoietin and stem cell factor receptors. Nature 1995; 377:242-6.
35. Dybedal I, Jacobsen SEW. Transforming growth factor β (TGF-β), a potent inhibitor of erythropoiesis: neutralizing TGF-β antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity. Blood 1995;86:949-57.
36. McNiece IK, Bertoncello I, Keller JR et al. Transforming growth factor beta inhibits the action of stem cell factor on mouse and human hematopoietic progenitors. Int J Cell Clon 1992;10:80-6.
37. + cells expanded in vitro. Exp Hematol 1994;22:1171-8.
38. Martinson JA, Unverzagt K, Schaeffer A et al. Neutrophil precursor generation: effects of culture conditions. J Hematother 1998;7: 463-71.
39. Koller MR, Manchel I, Palsson MA et al. Different measures of human hematopoietic cell culture performance are optimized under vastly different conditions. Biotech Bioeng 1996;50:505-13.
40. Palsson Bo, Paek SH, Schwartz RM et al. Expansion of human bone marrow progenitor cells in a high density continuous perfusion system. Bio/Technology 1993;11:368-72.
41. Lundell BI, Vredenbergh JJ, Tyer C et al. Ex vivo expansion of bone marrow from breast cancer patients: reduction in tumor cell content through passive purging. Bone Marrow Transplant 1998;22:153-9.
42. + peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. Blood 1996;88: 2707-13.
43. Barnett MJ, Eaves CJ, Phillips GL et al. Successful autografting in chronic myelogenous leukemia after maintenance of marrow in culture. Bone Marrow Transplant 1989;4:345-51.